Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796426 | 0.85 | HSD11B1 (0.73) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL30218271 | 0.85 | HSD11B1 (0.73) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL30822800 | 0.81 | HSD11B1 (1.00) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL2345581 | 0.81 | HSD11B1 (1.00) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL3495355 | 0.80 | HSD11B1 (0.66) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL2351157 | 0.80 | HSD11B1 (0.66) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL11034692 | 0.80 | HSD11B1 (0.73) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL10508168 | 0.79 | HSD11B1 (0.77) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL10954111 | 0.79 | HSD11B1 (0.81) | HSD11B1PTGS1PTGS2KDM4EUSP2 | |
| SCHEMBL10958729 | 0.79 | HSD11B1 (0.64) | HSD11B1PTGS1PTGS2KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614077-A | Meloxicam cocrystal | 迈兰实验室有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-2166060-B1 | Stabilized aqueous polymer compositions | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-8962715-B2 | Stabilized aqueous polymer compositions and their use | TOUGAS OILFIELD SOLUTIONS GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| US-20100075871-A1 | Stabilized aqueous polymer compositions and their use | TOUGAS HOLDING GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| EP-2166060-A1 | Stabilized aqueous polymer compositions and their use | Allessa Chemie GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| EP-1462451-B1 | NOVEL CRYSTALLINE FORMS OF MELOXICAM AND THE PREPARATION AND INTERCONVERSION METHODS THEREOF | ESTEVE QUIMICA SA (ES) | 2006-03-01 | — | — | EP | disclosed |
| US-6967248-B2 | Crystalline forms of meloxicam and processes for their preparation and interconversion | ESTEVE QUIMICA, SA (ES) | 2005-11-22 | — | — | US | disclosed |
| EP-1462451-A1 | NOVEL CRYSTALLINE FORMS OF MELOXICAM AND THE PREPARATION AND INTERCONVERSION METHODS THEREOF | ESTEVE QUIMICA, S.A. (ES) | 2004-09-29 | — | — | EP | disclosed |
| US-20030109701-A1 | Crystalline forms of meloxicam and processes for their preparation and interconversion | ESTEVE QUIMICA, S.A. (ES) | 2003-06-12 | — | — | US | disclosed |
| US-4797483-A | Process for obtaining 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide | INDUSPOL, S.A. (ES) | 1989-01-10 | — | — | US | disclosed |
| EP-0284514-A1 | Process for obtaining 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide | ESTEVE QUIMICA, S.A. (ES) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109701-A1 | Crystalline forms of meloxicam and processes for their preparation and interconversion | CRYAA, CRYAB, TTR | HSD11B1 2361/4885PTGS1 62/4885PTGS2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.